erlotinib hydrochloride has been researched along with trinitrobenzenesulfonic acid in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (trinitrobenzenesulfonic acid) | Trials (trinitrobenzenesulfonic acid) | Recent Studies (post-2010) (trinitrobenzenesulfonic acid) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 2,710 | 10 | 1,042 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Appleyard, CB; Coppola, D; Cruz, ML; Isidro, AA; Pagán, B; Ren, Y; Wu, J | 1 |
1 other study(ies) available for erlotinib hydrochloride and trinitrobenzenesulfonic acid
| Article | Year |
|---|---|
Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model.
Topics: Animals; Cell Line; Cell Proliferation; Colitis; Colon; Colonic Neoplasms; Disease Models, Animal; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Trinitrobenzenesulfonic Acid | 2011 |